HARFANG

HEOR

Mission: Provide strategic, actionable HEOR and market access expertise, integrating global and local perspectives to support biotech and pharmaceutical companies in securing and maintaining patient access to innovative therapies.

WHY WORK WITH US

Founded in 2023 by Marie-Josée Martel, PhD, Consultation Harfang HEOR inc. The "harfang des neiges" (snowy owl) was chosen as it is the avian emblem of Quebec (Canada), where Consultation Harfang HEOR is based. is a boutique consultancy providing tailored solutions and freelance support in global health economics and outcomes research (HEOR), epidemiology, and market access/HTA.

A dynamic leader with international experience

Strong scientific foundation: PhD in pharmacoepidemiology

Depth of expertise: global, regional, and local/affiliate roles

International viewpoint from working in Canada, USA and the UK

Lifecycle awareness: 20+ years leading activities supporting pipeline and marketed products

Agile and versatile: experience in large pharmaceutical companies, small biotechs, and healthcare consulting

Global team architect: Built, led and supported multidisciplinary international teams

Tangible experience: Hands-on and senior positions in HEOR, real-world evidence (RWE) and market access

Breadth of therapeutic expertise: including oncology, immunology, neuroscience, as well as rare diseases

A STRATEGIC PARTNER FOR YOUR TEAM

To enable you to focus on key priorities

 

  • N
    Freelance senior strategic support and assistance for HEOR, RWE and market access teams and leaders
  • N
    An independent sounding board, for strategic initiatives and insights, review of key HTA/payer submissions, communications and publications

To strengthen product value with scientifically sound evidence

 

  • N
    Integrated HEOR strategic planning and evidence generation/differentiation strategies
  • N
    Epidemiologic and real-world evidence (RWE) research and insights
  • N
    HTA landscape assessments and gap analyses
  • N
    Global and local value propositions and messaging

To ensure global and local market access perspectives are considered throughout product development

 

  • N
    Clinical trial inputs: endpoint/PRO selection, study design and patient experience data planning
  • N
    Early HTA scientific consultations and market access planning
  • N
    Stakeholder engagements, such as advisory board moderation and participation
error: